Q BioMed Inc. (QBIO)
|Net Income (ttm)||-11.02M|
|Trading Day||May 7|
|Day's Range||0.9200 - 0.9500|
|52-Week Range||0.8900 - 2.0500|
Q BioMed touts development progress of coronavirus treatment MAN-19 and other therapies in letter to shareholders
Q BioMed Inc (OTCQB:QBIO) has released a letter to shareholders, bringing them up to speed on the developments of its technology partner, Mannin Research, and its work to treat the coronavirus (COVID-19...
NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Researc...
Acquires undervalued biomedical assets to accelerate their development Developing drugs and therapies to treat pediatric nonverbal autism, liver cancer, and glaucoma Produces cancer bone-pain drug Stron...
Q BioMed announces five year contract with the US Department of Defense and Veterans Affairs for its cancer bone pain...
Q BioMed Inc (OTCQB:QBIO) has announced a supply contract with the US Department of Defense and Veterans Affairs (VA), which will make its cancer bone pain drug available to over 9 million VA beneficiar...
Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs
NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injecti...
Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Indep...
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Orga...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designatio...
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a close, we joi...
Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is a member ...
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; ... [Read more...]
|Stock Exchange |
|Ticker Symbol |